There is an independent monitoring review committee whose job it is to oversee the data and whether it is meeting its endpoints. What makes you think you should see the commercial in confidence data from the review committee? This is not some University Lab with the goal of publish or perish. RCE is trying to become a commercially viable pharma company and it is not in it's interests to share any more than they absolutely have to. You have been told what the primary and secondary endpoints are and you have been told that they have been met. If that isn't the case then RCE are lying to the market. Is that what you are claiming?
Ann: Positive Phase II Data from Clinical Trial of R327 Gel, page-24
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
38.8¢ |
Change
0.003(0.65%) |
Mkt cap ! $112.0M | |||
| Open | High | Low | Value | Volume |
| 38.5¢ | 39.0¢ | 38.0¢ | $4.167K | 10.76K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 24610 | 38.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 39.0¢ | 49817 | 1 |
View Market Depth
| Last trade - 15.44pm 31/07/2025 (20 minute delay) ? |
| RCE (ASX) Chart |